Merus (MRUS) said Tuesday the US Food and Drug Administration has extended the Prescription Drug User Fee Act objective deadline for experimental NRG1+ cancer treatment zenocutuzumab.
The regulator moved the deadline to Feb. 4 to allow more time to review recent information Merus submitted, the company said.
Price: 51.25, Change: +0.02, Percent Change: +0.03
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。